Coupling of Neural Activity and Retinal Blood Flow in Diabetes

NCT01375166 | Terminated DMC

• 1 other identifier: OPHT-070111
• Study Type: observational
• Target: 1
• Locations: 1 country
• Sites: 1

Brief Summary

The prevalence of diabetes is increasing and the management of the disease is nowadays considered a major challenge. Affected patients have increased mortality and morbidity as well as a significant drop in the quality of life. The complications of diabetes can be classified as microvascular (e.g. nephropathy, neuropathy or retinopathy) or macrovascular (e.g. cardiovascular or cerebrovascular). Several large-scale epidemiologic studies indicating that wider retinal venous caliber is strongly associated with the fasting glucose level as well as with diabetes. Another retinal vascular abnormality that is associated with diabetes is an abnormal retinal vascular response to flicker stimulation. Retinal vessel dilatation in response to stimulation with diffuse flicker light occurs due to a phenomenon called neurovascular coupling. This means that increased activity of neurons is associated with an increased retinal metabolism. This leads to a release of endogenous vasodilator substances and increased blood flow. However, previous studies were limited by the fact that retinal vessel diameters and blood flow were not measured simultaneously. The present study aims to investigate whether the response of retinal vessel diameters and blood flow velocities to flicker stimulation is altered in patients with diabetes. Both parameters will be measured in real time using Fourier Domain Doppler OCT.

Conditions

Diabetic Retinopathy

Outcome Measures

Primary Outcomes (2)

• Retinal vessel diameters

  18 months

• Retinal blood flow velocities

  18 months

Study Arms (2)

Diabetic retinopathy

Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy

healthy

healthy control subjects

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

24 patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy, non-smokers 24 age and sex matched healthy controls, non-smokers

You may qualify if:

• Men and women aged over 18 years, nonsmokers
• Normal findings in the medical history (except diabetes) and physical examination unless the investigator considers an abnormality to be clinically irrelevant
• normal laboratory findings (except diabetes associated parameters) unless the investigator considers the abnormality to be clinically irrelevant
• normal ophthalmic findings (except mild diabetic retinopathy), Ametropia less than 6 diopters

You may not qualify if:

• Any of the following will exclude a healthy subject from the study:
• Regular use of vasoactive drugs
• Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
• Symptoms of a clinically relevant illness in the 3 weeks before the first study day
• Blood donation during the previous 3 weeks
• History or presence of any ocular pathology
• History or family history of epilepsy
• Systemic hypertension defined as systolic blood pressure \>150mmHg, diastolic blood pressure \>90mmHg
• Pregnancy
• Any of the following will exclude a subject with diabetes from the study:
• Presence of non-insulin dependent diabetes, maturity onset diabetes of the young (MODY diabetes)
• History or presence of any other diabetes induced vascular pathologies or any other ocular condition other then diabetic retinopathy
• Best corrected visual acuity \<0.8
• Previous laser photocoagulation treatment
• Systemic hypertension defined as systolic blood pressure \>150mmHg, diastolic blood pressure \>90mmHg

Sponsors & Collaborators

• Medical University of Vienna: lead

Study Sites (1)

Department of Clinical Pharmacology

Vienna, 1090, Austria

Location

MeSH Terms

Conditions

Diabetic Retinopathy

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Study Officials

• Gerhard Garhöfer, MD

  Department of Clinical Pharmacology, Medical University of Vienna

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof. Priv. - Doz. Dr

Study Record Dates

• First Submitted: April 11, 2011
• First Posted: June 17, 2011
• Study Start: March 6, 2013
• Primary Completion: March 6, 2013
• Study Completion: March 6, 2013
• Last Updated: February 20, 2020

Record last verified: 2020-02

Locations

AU (1)